Urine Molecular Biomarkers for Detection and Follow-Up of Small Renal Masses

Autor: Algirdas Žalimas, Raimonda Kubiliūtė, Kristina Žukauskaitė, Rasa Sabaliauskaitė, Mantas Trakymas, Simona Letautienė, Edita Mišeikytė Kaubrienė, Jurgita Ušinskienė, Albertas Ulys, Sonata Jarmalaitė
Rok vydání: 2022
Předmět:
Zdroj: International journal of molecular sciences, Basel : MDPI AG, 2022, vol. 23, iss. 24, art. no. 16110, p. 624-634
International Journal of Molecular Sciences; Volume 23; Issue 24; Pages: 16110
ISSN: 1422-0067
1661-6596
Popis: Active surveillance (AS) is the best strategy for small renal masses (SRMs) management; however, reliable methods for early detection and disease aggressiveness prediction are urgently needed. The aim of the present study was to validate DNA methylation biomarkers for non-invasive SRM detection and prognosis. The levels of methylated genes TFAP2B, TAC1, PCDH8, ZNF677, FLRT2, and FBN2 were evaluated in 165 serial urine samples prospectively collected from 39 patients diagnosed with SRM, specifically renal cell carcinoma (RCC), before and during the AS via quantitative methylation-specific polymerase chain reaction. Voided urine samples from 92 asymptomatic volunteers were used as the control. Significantly higher methylated TFAP2B, TAC1, PCDH8, ZNF677, and FLRT2 levels and/or frequencies were detected in SRM patients’ urine samples as compared to the control. The highest diagnostic power (AUC = 0.74) was observed for the four biomarkers panel with 92% sensitivity and 52% specificity. Methylated PCDH8 level positively correlated with SRM size at diagnosis, while TFAP2B had the opposite effect and was related to SRM progression. To sum up, SRMs contribute significantly to the amount of methylated DNA detectable in urine, which might be used for very early RCC detection. Moreover, PCDH8 and TFAP2B methylation have the potential to be prognostic biomarkers for SRMs.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje